TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
05. September 2024 07:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
ImmunOs Therapeutics Expands Phase I Clinical Trial of IOS-1002 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Solid Tumors
24. Juli 2024 04:00 ET
|
AKAMPION
Dosing of patients in new combination treatment arm – IOS-1002 plus KEYTRUDA Schlieren (Zurich Area), Switzerland – July 24, 2024 – ImmunOs Therapeutics AG, a biopharmaceutical company using its...
Lung Cancer Therapeutics Market Size Worth USD 57.69 Billion in 2032 | Emergen Research
04. Januar 2024 07:45 ET
|
Emergen Research
Vancouver, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The global lung cancer therapeutics market size was USD 28.00 Billion in 2022 and is expected to register a rapid revenue CAGR of 7.7% during the...
1ST Biotherapeutics, Inc. Announces First Patient Dosed in Phase I/II Study of HPK1 Inhibitor FB849 in Patients with Advanced Solid Tumors
14. Dezember 2023 04:00 ET
|
AKAMPION
YONGIN, South Korea, December 14, 2023 – 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics in neurodegenerative...
HistoSonics Edison System Recognized With BioTech Breakthrough Award For “MedTech Innovation Of The Year”
08. November 2023 08:02 ET
|
BioTech Breakthrough
LOS ANGELES, Nov. 08, 2023 (GLOBE NEWSWIRE) -- BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology...
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
03. Oktober 2023 07:50 ET
|
Purple Biotech Ltd.
Anti-tumor activity noted in the highest dose cohort of NT219 in combination with cetuximab; 2 out of 4 SCCHN patients at the highest dose cohort demonstrated a confirmed partial responseNT219...
Photodynamic Therapy Market to Grow at a CAGR of 13.5% from 2022 to 2031, reaching US$ 15.5 Billion: As per TMR Study
17. Juli 2023 15:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, July 18, 2023 (GLOBE NEWSWIRE) -- The global photodynamic therapy market stood at US$ 4.2 billion in 2021, and the global market is projected to reach US$ 15.5...
Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors
19. April 2023 08:15 ET
|
Purple Biotech Ltd.
New preclinical data from study presented at the American Association for Cancer Research 2023 Annual Meeting, 18 April 2023 REHOVOT, Israel, April 19, 2023 (GLOBE NEWSWIRE) -- Purple Biotech...
Epirubicin Market Worth $243.99 Million, Globally, by 2028 at 3.6% CAGR - Exclusive Report by The Insight Partners
22. Juli 2022 06:56 ET
|
The Insight Partners
New York, July 22, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Epirubicin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Dosage (10mg/Vial,...
Vivos Inc. Enhances its Intellectual Property Protection
24. Februar 2022 09:30 ET
|
Vivos Inc.
Richland WA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it filed its particle patent in several countries. Our new patent team filed the...